US Patent

US10383853 — Carboxamide derivative and its diastereomers in stable crystalline form

Composition of Matter · Assigned to Orion Oyj · Expires 2036-01-28 · 10y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects stable crystalline forms of a specific carboxamide derivative and its diastereomers, which are potent androgen receptor modulators.

USPTO Abstract

The present disclosure relates to solid crystalline forms of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.

Drugs covered by this patent

Patent Metadata

Patent number
US10383853
Jurisdiction
US
Classification
Composition of Matter
Expires
2036-01-28
Drug substance claim
Yes
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.